EUVIMEDSkopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC-ND 4.0

Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy

Thorsten Oliver Goetze, Alexander Stein, Sylvie Lorenzen, Timorshah Habibzada, Eray Goekkurt, Peter Herhaus, Maria Loose iD, Disorn Sookthai, Tanita Brulin, Kristina Ihrig, Claudia Pauligk, Salah-Eddin Al-Batran

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34652 ↗

At a glance

Multizentrische Studie in International Journal of Cancer, 2023. Written by Thorsten Oliver Goetze and 11 co-authors. Institution: Institute for Clinical Cancer Research IKF, Frankfurt, Germany. Major MEDLINE topics: Adenocarcinoma, Stomach Neoplasms. Cited 7 times so far (Crossref); 18 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Lilly Deutschland.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS‐102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non‐randomized, open‐label, investigator‐initiated pilot trial, ramucirumab‐pretreated patients with metastatic EGA received a maximum of 4 cycles of ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS‐102 (35 mg/m 2 p.o. bid on day 1‐5 and day 8‐12; Q2W). Primary endpoint was tolerability and toxicity, defining a positive trial if the SAE rate according to CTCAE 5.0 will increase

Subjects

MeSH terms (MEDLINE)

AdenocarcinomaStomach NeoplasmsHumansTrifluridineAntineoplastic Combined Chemotherapy ProtocolsTreatment FailureEsophagogastric JunctionRamucirumabDrug CombinationsPyrrolidinesThymine

Author keywords

TAS-102metastatic esophagogastric adenocarcinomaramucirumabtreatment beyond progression

Substances

TrifluridineRamucirumabtrifluridine tipiracil drug combinationDrug CombinationsPyrrolidinesThymine

Authors and institutions

  • Institute for Clinical Cancer Research IKF, Frankfurt, Germany.
  • University Cancer Center Frankfurt, Krankenhaus Nordwest, Frankfurt, Germany.
  • University Cancer Center Frankfurt, Goethe University, Frankfurt, Germany.
  • Hämatologisch-Onkologische Praxis Eppendorf (HOPE) und Universitäres Cancer Center Hamburg (UCCH), Hamburg, Germany.
  • München Klinikum rechts der Isar der TU München III. Medizinische Klinik und Poliklinik, Munich, Germany.

ORCID profiles: Maria Loose

Funding

  • Lilly Deutschland

Cite

APA

Goetze, T. O., Stein, A., Lorenzen, S., Habibzada, T., Goekkurt, E., Herhaus, P., Loose, M., Sookthai, D., Brulin, T., Ihrig, K., Pauligk, C., & Al-Batran, S. E. (2023). Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.34652

Vancouver

Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, et al. Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. 2023. doi:10.1002/ijc.34652

BibTeX
@article{Goetze2023,
  author = {Goetze, Thorsten Oliver and Stein, Alexander and Lorenzen, Sylvie and Habibzada, Timorshah and Goekkurt, Eray and Herhaus, Peter and Loose, Maria and Sookthai, Disorn and Brulin, Tanita and Ihrig, Kristina and Pauligk, Claudia and Al-Batran, Salah-Eddin},
  title = {Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34652}
}
Start for free →